F11R anticorps (Extracellular Domain) (FITC)

N° du produit ABIN1106269

Cet anticorps Souris Monoclonal détecte spécifiquement F11R dans WB, FACS, IF et IHC (fro). Il présente une réactivité envers Humain.

Aperçu rapide pour F11R anticorps (Extracellular Domain) (FITC) (ABIN1106269)

Antigène: F11R (F11 Receptor (F11R))

Reactivité: Humain

Hôte: Souris

Clonalité: Monoclonal

Conjugué: Cet anticorp F11R est conjugé à/à la FITC

Application: Western Blotting (WB), Flow Cytometry (FACS), Immunofluorescence (IF), Immunohistochemistry (Frozen Sections) (IHC (fro))

Clone: BV16

Détail du produit anti-F11R anticorps (FITC)

Épitope: Extracellular Domain

Specificité: The monoclonal antibody BV16 recognizes the human junction adhesion molecule (JAM)-A.

Réactivité croisée (Details): Species reactivity (tested):Human

Purification: Potein G

Immunogène: Fusion protein consisting of the extracellular domain of human JAM and the Fc portion of human IgGs

Isotype: IgG1

Information d'application

Indications d'application: Optimal working dilution should be determined by the investigator.

Restrictions: For Research Use only

Stockage

Concentration: 0.1 mg/mL

Buffer: PBS, 0.02 % sodium azide, 1 % bovine serum albumin

Agent conservateur: Sodium azide

Précaution d'utilisation: This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Conseil sur la manipulation: Avoid repeated freezing and thawing.

Stock: 4 °C/-20 °C

Stockage commentaire: Prior to reconstitution store at 2-8 °C. Following reconstitution store undiluted at 2-8 °C for one month or or (in aliquots) at -20 °C for longer.

Détails sur F11R

Antigène: F11R (F11 Receptor (F11R))

Autre désignation: CD321 / JAM1

Sujet: Together with JAM-C (JAM-2) and JAM-B (VE-JAM or JAM-3), JAM-A belongs to a family of adhesion proteins with a V-C2 immunoglobulin domain organization and their molecular weight is about 30-40 kDa. JAMs are important for a variety of cellular processes, including tight junction assembly, leukocyte transmigration, platelet activation, angiogenesis and virus binding. JAM-A is expressed by endothelial and epithelial cells, platelets, neutrophils, monocytes, lymphocytes and erythrocytes. Like all other JAMs, JAM-A plays an important role in tight junctions where it is involved in cell-to-cell adhesion through homophilic interaction. It codistributes with other tight junction components as ZO-1, 7H6 antigen, cingulin and occludin. JAM-A also plays an important role in leukocyte transmigration. Leukocyte transmigration can be blocked by antibodies and by soluble JAM-A/Fc fusion proteins. Homophilic JAM-A interactions between leukocytes and the endothelium but also heterophilic interactions of JAM-A with the beta2-integrin leukocyte function-associated antigen-1 (LFA-1) are considered to actively guide leukocytes during transmigration. Several studies imply a role for JAM-A in the initiation of atherosclerosis since JAM-A is upregulated on early atherosclerotic endothelium. The adhesion of activated platelets on the activated endothelium is mediated by homophilic interactions of JAM-A.Synonyms: F11R, JAM-A, JCAM, Junctional adhesion molecule 1, Junctional adhesion molecule A, PAM1, Platelet F11 receptor, Platelet adhesion molecule 1

ID gène: 50848

NCBI Accession: NP_058642

UniProt: Q9Y624

Pathways: Cell-Cell Junction Organization